“While GLP-1-based therapies have revolutionized ... wanted to see if they could create medication that curbs appetite and ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Stopping semaglutide, marketed as Wegovy and Ozempic, which helps people lose weight , can have severe health impacts, a new ...

Preliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...

Early studies show a drug can effectively 'switch on' particular cells within the nervous system that play an important role ...

Dr, Garner said, "Glucagon-like peptide-1 (GLP-1) receptor agonists represent a significant advancement in the treatment of ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...